ZYBERNO
Stock Report
Updated Sep 1, 2026

BRIACELL THERAPEUTICS CORP. (BCTX)

Healthcare • NASDAQ

$3.59

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
BRIACELL THERAPEUTICS CORP. (BCTX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-152.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-193.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BRIACELL THERAPEUTICS CORP. (BCTX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.59
Market Cap:$26.03M

Valuation Multiples (2)

P/B Ratio:1.11x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$19.15M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-128.6%
Reinvestment Rate:-1.1%
Fundamental Growth Rate (g):2.2%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$1.92K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:89.8%
Latest Earnings Filed:2026-06-09
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.07x
Quick Ratio:7.07x
Cash Ratio:1.92x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-918.12x
Times Interest Earned:-918.12

Capital Structure (4)

Working Capital:21,802,678.00
Cash And Cash Equivalents:6,880,221.00
Long Term Debt:$0.00
Net Debt:-$6.88M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$32.03M

Bottom Line Performance (3)

-$30.68M
Income Before Tax:$26.56M
Ebitda Ttm:-31,937,920.00

Operating Expenses (5)

Operating Expenses:32,029,276.00
R And D Expense:25,814,369.00
Sga Expense:6,214,907.00
Income Tax Expense:$0.00
Interest Expense:29,631.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$27.07M
Current Assets:$25.39M
Ppe Net:348,997.00
Goodwill:0.00
Intangible Assets:$180.71K

Liability Structure (4)

Total Liabilities:3,662,350.00
Current Liabilities:3,590,496.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$23.41M
Retained Earnings:-$134.34M
Common Stock:117,117,225.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:0.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:285,856.00
C. Cash Flow Analysis

Operating Activities (2)

-$28.92M-$28.63M

Investment Activities (1)

Investing Cash Flow:-$75.00K

Financing Activities (3)

Financing Cash Flow:$13.56M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:44,627,224.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:91,356.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-65.92
-$65.92
Earnings Per Share Ttm:-$4.23

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.89

Book Value & Capital (2)

Book Value Per Share:$3.23
Cash Per Share:0.95

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.1%
Fundamental Growth Rate (g):2.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:BCTX
Company Name:BRIACELL THERAPEUTICS CORP.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Canada

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:7.25M
Shares Outstanding Basic:7.25M
Shares Outstanding Diluted:7.25M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 09:32:28 UTC
Data Timestamp:2026-08-20T23:41:12.217344
Scroll to Top